Randomised clinical trial: Arbaclofen placarbil in gastro-oesophageal reflux disease - Insights into study design for transient lower sphincter relaxation inhibitors

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 2, 2013, Pages 107-117

  Vakil, N B ^a   Huff, F J ^b   Cundy, K C ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b XenoPort Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARBACLOFEN PLACARBIL; PLACEBO; PROTON PUMP INHIBITOR; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; BACLOFEN; CENTRAL MUSCLE RELAXANT;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; LOW DRUG DOSE; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SOMNOLENCE; TREATMENT DURATION; VOMITING; XEROSTOMIA; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; BACLOFEN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ESOPHAGEAL SPHINCTER, LOWER; FEMALE; GABA-B RECEPTOR AGONISTS; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; MALE; MIDDLE AGED; MUSCLE RELAXANTS, CENTRAL; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 84879234558     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12363     Document Type: Article

References (17)

1. Jones R, Armstrong D, Malfertheiner P, Ducrotté P,. Does the treatment of gastroesophageal reflux disease (GERD) meet patients' needs? A survey-based study. Curr Med Res Opin 2006; 22: 657-62.
2. Keywood C, Wakefield M, Tack J,. A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut 2009; 58: 1192-9.
3. Boeckxstaens GE, Beaumont H, Mertens V, et al,. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology 2010; 139: 409-17.
4. Gerson LB, Huff FJ, Hila A, et al,. Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol 2010; 105: 1266-75.
5. Kim GH,. Arbaclofen placarbil decreases reflux with good tolerability in patients with gastroesophageal reflux disease. J Neurogastroenterol Motil 2010; 16: 444-5.
6. Shaheen NJ, Denison H, Björck K, Karlsson M, Silberg DG,. Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial. Gut 2012; 61: 1501-9.
7. Vakil NB, Huff FJ, Bian A, Jones DS, Stamler D,. Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2011; 106: 1427-38.
8. Kahrilas PJ, Boeckxstaens G,. Failure of reflux inhibitors in clinical trials: bad drugs or wrong patients? Gut 2012; 61: 1501-9.
9. Zerbib F, Duriez A, Roman S, Capdepont M, Mion F,. Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors. Gut 2008; 57: 156-60.
10. Lidums I, Lehmann A, Checklin H, Dent J, Holloway RH,. Control of transient lower esophageal sphincter relaxations and reflux by the GABAb agonist baclofen in normal subjects. Gastroenterology 2000; 118: 7-13.
11. Beaumont H, Boeckxstaens GE,. Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy? Am J Gastroenterol 2009; 104: 1764-71.
12. Vela M, Tutuian R, Katz PO, Castell DO,. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003; 17: 243-51.
13. Cossentino MJ, Mann K, Armbruster SP, Lake JM, Maydonovitch C, Wong RK,. Randomised clinical trial: the effect of baclofen in patients with gastro-oesophageal reflux-a randomised prospective study. Aliment Pharmacol Ther 2012; 35: 1036-44.
14. Lal R, Sukbuntherng J, Tai EH, et al,. Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen. J Pharmacol Exp Ther 2009; 330: 911-21.
15. Zerbib F, Bruley des Varannes S, Roman S, et al,. Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2011; 33: 911-21.
16. Development of ADX10059 ended for long-term use [press release]. Geneva, Switzerland: Addex Therapeutics; December 15, 2009. Available at: http://www.addextherapeutics.com/investors/press-releases/news-details/? tx-ttnews[tt-news]%20 = 88&cHash=d075a6fa63acce925582f8f481fb8dc3. Accessed October 27, 2012.
17. ClinicalTrials.gov. Selective 5-HT4 receptor agonist and proton pump inhibitor (PPI) in subjects with gastroesophageal reflux disease (GERD). Available at: http://www.clinicaltrials.gov/ct2/show/NCT01472939?term= shire+and+GERD&rank=1. Accessed October 27, 2012.